Mark Talamonti to Adalimumab
This is a "connection" page, showing publications Mark Talamonti has written about Adalimumab.
Connection Strength
0.615
-
Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study. J Eur Acad Dermatol Venereol. 2018 Oct; 32(10):1737-1744.
Score: 0.591
-
Evaluation of clinical and ultrasonographic parameters in psoriatic arthritis patients treated with adalimumab: a retrospective study. Clin Dev Immunol. 2012; 2012:823854.
Score: 0.024